Clinical trials: Neoplasia Prostate
Metastatic Castration-resistant Prostate Cancer
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled.
- Trial name
- PRESERVE-006 (NCT05682443)
- Testing
- ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
- Where
- 23 sites in United States
- Volunteers
- 148 people
- Sponsor
- OncoC4, Inc.
Prostate Cancer
Recommended Dose Estimation of BP-C2
The aim is to estimate an oral administered recommended dose of BP-C2 in addition to hormone treatment of prostate cancer. The study population consists of prostatic cancer patients between 18 and 80 years of age undergoing…
- Trial name
- NCT04186585
- Testing
- BP-C2
- Where
- Norway
- Volunteers
- 8 people
- Sponsor
- Meddoc
Oligometastatic Prostate Carcinoma
Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer
The optimal treatment for oligometastatic prostate cancer (OMPC) is still on its way. Accumulating evidence has proven the safety and feasibility of radical prostatectomy and local or metastasis-directed radiotherapy for…
- Trial name
- NCT05707468
- Testing
- ADT combined with abiraterone, neoadjuvant hormone and RT
- Where
- 6 sites in China
- Volunteers
- 200 people
- Sponsor
- Changhai Hospital
Metastatic Castration-resistant Prostate Cancer (CRPC)
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
- Trial name
- NCT06249750
- Testing
- Immunotherapy, Targeted therapy, Hyperthermia
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Pengyuan Liu
Prostate Cancer
Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients
There are two parts to this study: (1) an information gathering phase leading to development of a new decision aid (phase 1); and (2) a study to test the newly developed decision aid (phase 2).
- Trial name
- NCT00815750
- Testing
- Information Gathering, Decision Aid
- Where
- 2 sites in United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Prostate Cancer Patient Management With 18F-DCFPyL PET/CT
This is a multi-center, single-arm, open-label, phase III trial in patients with biopsy-proven prostate cancer. Patients will receive regular standard of clinical care.
- Trial name
- NCT03459820
- Testing
- 18F-DCFPyL PET/CT
- Where
- Canada
- Volunteers
- 1,500 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Prostate Cancer
Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation
Many reports of clinical outcomes following treatment of localized prostate cancer suffer from lack of prospective long-term data using objective and validated outcome instruments.
- Trial name
- NCT07203482
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- NYU Langone Health
Prostate Carcinoma
Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer
This phase I trial studies the impact of monosodium glutamate (MSG) on 68GA-PSMA-11 PET/CT in decreasing the salivary glands uptake in patients with prostate cancer.
- Trial name
- MSG PSMA PET (NCT04282824)
- Testing
- Biospecimen Collection, Computed Tomography, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Gastrointestinal Cancer, Prostate Cancer
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease. The primary evaluation criterion is clinical benefit response.
- Conditions
- Gastrointestinal Cancer, Prostate Cancer, Genital Neoplasms, Female
- Trial name
- NCT00332280
- Testing
- AMT2003
- Where
- 2 sites in Bosnia and Herzegovina, Germany
- Volunteers
- 67 people
- Sponsor
- Auron Healthcare GmbH
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
GU-01: Glycyrrhizin in Prostate Cancer
This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)
- Trial name
- GU-01 (NCT06378346)
- Testing
- Observation, Glycyrrhizin - 75 mg, Glycyrrhizin - 150 mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Illinois Chicago
Prostate Cancer
Active Surveillance Plus (AS+): High-intensity Focused Ultrasound (HIFU) in Patients With Localized Prostate Cancer
PSA (Prostate-specific antigen) testing has significantly increased the number of men diagnosed with prostate cancer (PCa) and especially patients with low and intermediate risk disease.
- Trial name
- NCT04549688
- Testing
- high-intensity focused ultrasound, HIFU
- Where
- Norway
- Volunteers
- 250 people
- Sponsor
- The Hospital of Vestfold
Prostate Cancer
Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer
The purpose of this study is to test an approach of stimulating the body's immune system to attack prostate cancer. This study will test injection of a substance polylysine and carboxymethylcellulose (Poly-ICLC, Hiltonol®)through…
- Trial name
- NCT03262103
- Testing
- Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ashutosh Kumar Tewari
Prostatic Neoplasm
Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
Prostate cancer is the 2nd most common cancer in men worldwide. Based on the results of several recent clinical trials, systemic treatments including hormone inhibitors, docetaxel, cabazitaxel, and PARP inhibitors are being used…
- Trial name
- NCT06236789
- Testing
- Ifosfamide/mesna
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Cardiovascular Risk, Prostate Cancer
The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT
Prostate cancer is characterised by its slow progression nature, and even for metastatic disease, the 5-year survival is up to 30%.
- Trial name
- NCT06163924
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)
Significant advances in molecular nuclear medicine imaging in prostate cancer have been achieved in recent years. In particular, the introduction of prostate-specific membrane antigen (PSMA) -based tracers has significantly…
- Trial name
- ProsTone (NCT04271579)
- Testing
- Salvage Lymphnode dissection
- Where
- Germany
- Volunteers
- 397 people
- Sponsor
- Martini-Klinik am UKE GmbH
Castration-resistant Prostate Cancer, Stage IV Prostate Cancer
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
This randomized phase II trial studies the best way to give abiraterone acetate in treating patients with castration-resistant prostate cancer.
- Trial name
- NCT01543776
- Testing
- abiraterone acetate
- Where
- 6 sites in United States, Singapore
- Volunteers
- 72 people
- Sponsor
- University of Chicago
Prostate Cancer
Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer
BACKGROUND: -This study represents a progression from findings in four previous National Cancer Institute (NCI) Radiation Oncology Branch (ROB) protocols (02-C-0167A, 02-C-0207E, 03-C-0190B, 04-C-0171).
- Trial name
- NCT00124917
- Testing
- Radiation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Erectile Dysfunction, Prostate Cancer
Intra-operative Neuromodulation of the Pelvic Plexus
The purpose of this study is to evaluate the feasibility of electrical stimulation of nerves responsible for erectile function to evoke penile erection after surgery to remove the prostate (prostatectomy).
- Trial name
- NCT03425240
- Testing
- Nerve Stimulation
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- Laikο General Hospital, Athens
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.